Human research · RCT
Franco S et al., Pain Research and Management 2026
In a manufacturer-sponsored, double-blind, sham-controlled RCT of 64 adults with painful diabetic peripheral neuropathy (DPN), 3 weeks of twice-daily home use of a dual-wavelength (640 nm red + 405 nm violet) low-level laser device on the feet gave more people at least a 30% drop in foot pain than sham (72.7% vs 32.3%, intention-to-treat with imputation). Short-term pain outcome only (to week 7), small trial, and the active arm guessed its allocation above chance.
Source: Dual-Wavelength Laser Therapy for Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, and Sham-Controlled Trial. Franco S, Lara C, Gair K, Zang K, Franco J, Shanks S, Sammons T. Pain Research and Management. 2026;2026:8710857. doi:10.1155/prm/8710857. PMID:42860829. PMCID:PMC13655509. Published 2026-10-11. ClinicalTrials.gov NCT05291975. Full text read (PMC) plus registry record and posted results
Verified research card EL-20261018-07-R2